Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
Kyverna Therapeutics, a late‑stage biopharma focused on cell therapies for autoimmune diseases, announced the hiring of Nadia Dac as its new chief commercial officer, effective May 4, 2026. Dac brings over three decades of commercial leadership experience in neurology and rare disease markets. The appointment was disclosed in a GlobeNewswire release on May 4, 2026.
Advertisement: Article Inline